Pregabalin misuse in methadone maintenance treatment patients in Israel: Prevalence and risk factors
•Methadone maintenance treatment patients misuse pregabalin.•High prevalence (17.7%) of pregabalin was detected in urine tests.•Risk factors includes benzodiazepine and high depressive score.•Pregabalin misuse was detected also in patients with take-home medication privileges. Drug users reportedly...
Gespeichert in:
Veröffentlicht in: | Drug and alcohol dependence 2018-08, Vol.189, p.8-11 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •Methadone maintenance treatment patients misuse pregabalin.•High prevalence (17.7%) of pregabalin was detected in urine tests.•Risk factors includes benzodiazepine and high depressive score.•Pregabalin misuse was detected also in patients with take-home medication privileges.
Drug users reportedly abuse pregabalin, and its combination with opiates was related to fatalities. We aimed to estimate the prevalence of pregabalin misuse and risk factors among patients in methadone maintenance treatment (MMT).
A cross-sectional study included all current MMT patients (n = 300) after excluding 9 with prescriptions, from a large tertiary medical center university-affiliated MMT clinic in Israel. Pregabalin was tested in one of the routine urine tests for other substances in December 2017. Data on urine results and patients’ characteristics were retrieved from the patients’ records.
Pregabalin was detected among 53 (17.7%) patients. The group had higher depressive symptoms severity score (21-HAM-D) (11.1 ± 8.4 vs. 8.3 ± 7.8, p = 0.03), a higher prevalence of sero-positive HIV (13.7% vs. 4.2%, p = 0.02), sero-positive hepatitis C (66.7% vs. 50.4%, p = 0.04), DSM-IV-TR Axis I psychiatric diagnosis (54.0% vs. 41.7%, p = 0.03), and positive urine for opiates (22.6% vs. 8.9%, p = 0.008), cannabis (39.6% vs. 4.0 p |
---|---|
ISSN: | 0376-8716 1879-0046 |
DOI: | 10.1016/j.drugalcdep.2018.04.025 |